Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8084718 | 0.84 | SMN1; SMN2 (0.46) | MAPTALDH1A1LMNASMN1; SMN2KMT2A | |
| SCHEMBL7968279 | 0.81 | GAA (0.43) | MAPTALDH1A1LMNAKMT2AHTT | |
| SCHEMBL2102798 | 0.81 | GAA (0.43) | MAPTALDH1A1LMNAKMT2AHTT | |
| SCHEMBL696232 | 0.81 | GAA (0.43) | MAPTALDH1A1LMNAKMT2AHTT | |
| SCHEMBL7985048 | 0.81 | GAA (0.43) | MAPTALDH1A1LMNAKMT2AHTT | |
| SCHEMBL10120229 | 0.79 | ITGB2 (0.48) | MAPTALDH1A1LMNASMN1; SMN2KMT2A | |
| SCHEMBL10120707 | 0.76 | MAPT (0.41) | MAPTALDH1A1LMNAKMT2AENPP2 | |
| SCHEMBL14144882 | 0.76 | MAPT (0.40) | MAPTALDH1A1LMNASMN1; SMN2KMT2A | |
| SCHEMBL31013539 | 0.75 | PRKCQ (0.45) | MAPTALDH1A1LMNAENPP2 | |
| SCHEMBL28974721 | 0.75 | PRKCQ (0.45) | MAPTALDH1A1LMNAENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790721-B2 | Pyrroloquinoxalinone inhibitors of poly(ADP-ribose)polymerase | ABBOTT LABORATORIES (US) | 2010-09-07 | — | — | US | disclosed |
| US-20080161292-A1 | INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | ABBOTT LABORATORIES (US) | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161292-A1 | INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | PARP1, PARP2, PARP3 | MAPT 3017/4885ALDH1A1 1358/4885LMNA 688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.